

2 February 2022

Dear CLN1 Batten disease Community,

In December, we announced the Clinical Trial Application (CTA) approval by Health Canada for a Phase 1/2 clinical trial of TSHA-118, Taysha's investigational gene therapy for infants and children living with CLN1 disease, a form of Batten disease. Receiving CTA approval means that the regulatory authorities in Canada have reviewed and approved the clinical trial plans for TSHA-118. We are in the final stages of reviewing the clinical trial plans with the proposed site.

We are planning a webinar to present a general overview of the CLN1 (TSHA-118) clinical trial highlighting our commitment to the CLN1 disease community. The webinar will occur once the clinical trial site is open and ready to enroll patients with CLN1 disease. You are welcome to submit any questions you may have about the TSHA-118 clinical trial to the patient advocacy groups [BDSRA](#) and [BDFa](#) prior to the webinar. Please submit your questions by February 18, 2022, to either BDSRA or BDFa. The date of the webinar is still to be determined, and we will work with the patient advocacy groups to invite the CLN1 disease community once the webinar is scheduled.

Additionally, Taysha will be attending the WORLDSymposia February 7-11 where our Medical Affairs team plans to present a medical poster of the proposed TSHA-118 clinical trial design.

As you may be aware, in patients with CLN1 disease, the body does not make enough of the enzyme palmitoyl protein thioesterase 1 (PPT1), which is needed to break down a complex substance in the cells made up of protein and fat. TSHA-118 is intended to deliver a healthy copy of the *PPT1* gene, formerly known as the *CLN1* gene, through an adeno-associated virus serotype 9 (AAV9) vector which will be investigated in the clinical trial.

We are continually grateful for your support and remain committed to the safety of the patients we serve. We look forward to sharing a general overview of the program during the upcoming webinar and will continue to provide updates on the trial as further details become available while working with our patient advocacy groups.

**Sincerely,
The Taysha Team**

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely, including those described in our filings with the Securities and Exchange Commission, which is available at www.sec.gov. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law

© Taysha Gene Therapies 2022. All rights reserved. TSHA-CL1-0090-2022

